
Voyager Therapeutics (VYGR) Stock Forecast & Price Target
Voyager Therapeutics (VYGR) Analyst Ratings
Bulls say
Voyager Therapeutics Inc is positioned positively due to its robust TRACER platform, which is expected to generate increasing revenues from collaborations advancing to clinical trials in the 2030s. The company's innovative approach in gene therapy demonstrates significant early clinical results, particularly with VY1706, which showed a reduction in tau messenger RNA by up to 73% in non-human primates, indicating promising efficacy. Furthermore, recent preclinical data suggests that Voyager's NeuroShuttle technology offers enhanced durability and safety advantages over existing therapies, strengthening its potential in the competitive neurology market.
Bears say
The financial outlook for Voyager Therapeutics Inc appears unfavorable due to significant operational losses that have led to dwindling cash reserves, raising concerns about the company's ability to fund ongoing research and development efforts. Additionally, the lack of substantial progress in advancing its therapeutic pipeline and the increasing competition in the gene therapy space pose risks to future revenue generation and market positioning. These factors, combined with the uncertainty surrounding clinical trial outcomes, contribute to a negative assessment of the company's financial viability and growth prospects.
This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Voyager Therapeutics (VYGR) Analyst Forecast & Price Prediction
Start investing in Voyager Therapeutics (VYGR)
Order type
Buy in
Order amount
Est. shares
0 shares